Olanib 150 mg | Generic Olaparib by Everest Pharmaceuticals

Description

Dr. Daria Kwaśniewska ESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.

Is Olanib 150 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓BRCA1/2-mutated ovarian, fallopian tube, or primary peritoneal cancer, including maintenance after platinum chemotherapy
✓Germline BRCA-mutated, HER2-negative metastatic breast cancer previously treated with chemotherapy
✓BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer
✓Need a WHO-GMP generic alternative to Lynparza® (AstraZeneca)

✖ May NOT be suitable if

✗No confirmed BRCA mutation or HRR gene alteration (genetic testing is mandatory before starting)
✗Pre-existing myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)
✗Pregnant, planning pregnancy, or breastfeeding
✗Severe renal impairment without oncologist dose adjustment

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Olanib 150 mg?

Olanib 150 mg is a generic formulation of Olaparib — a first-in-class PARP (Poly ADP-ribose Polymerase) inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 150 mg of olaparib, the same active molecule found in Lynparza® (AstraZeneca), and is dispensed under the Named Patient Program for patients with BRCA-mutated or HRR-deficient cancers requiring an affordable, quality-assured alternative.

Olaparib is approved across four cancer types — ovarian, breast, prostate, and pancreatic — each linked by a shared genetic vulnerability: deficiency in the homologous recombination repair (HRR) pathway, most commonly caused by BRCA1 or BRCA2 mutations.

Generic name	Olaparib
Reference brand	Lynparza® (AstraZeneca)
Manufacturer	Everest Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	PARP Inhibitor
Dosage form	Film-coated tablet — 150 mg
Pack size	120 tablets per pack (30-day supply)
Route	Oral · twice daily
Prescription	Required — oncologist only

How Olaparib Works

Healthy cells have multiple backup pathways to repair damaged DNA. Cancer cells with BRCA1 or BRCA2 mutations have already lost one major repair pathway (homologous recombination repair) and depend heavily on a backup enzyme called PARP to survive. Olaparib blocks PARP, leaving these cancer cells with no functioning way to repair their DNA — a strategy known as synthetic lethality.

Because healthy cells retain their normal DNA repair pathways, they are largely spared from olaparib’s effect — this selectivity is what distinguishes PARP inhibitors from traditional chemotherapy. In the SOLO-1 trial, olaparib maintenance reduced the risk of disease progression or death by 70% in newly diagnosed BRCA-mutated advanced ovarian cancer. NCCN guidelines list olaparib as a Category 1 recommendation for BRCA-mutated ovarian, breast, prostate, and pancreatic cancers. View NCCN Ovarian Cancer Guidelines →

What to Expect: First 30 Days

Olaparib is generally well tolerated for a maintenance therapy, though gastrointestinal symptoms and blood count changes are common in the early weeks.

Week 1: Nausea is the most common early symptom — taking the medication at bedtime can help. Mild fatigue is also common as your body adjusts to twice-daily dosing.
Weeks 2–3: Blood counts begin to be monitored closely — particularly red blood cells, white blood cells, and platelets. A drop in haemoglobin (anaemia) is common and your oncologist may adjust monitoring frequency accordingly.
Week 4: Most patients have adjusted to the routine. Your oncologist will review blood counts and overall tolerability and may discuss long-term monitoring plans, since olaparib is often a long-duration maintenance therapy.

Side Effects

Most side effects are manageable, but olaparib carries rare but serious risks that require ongoing monitoring throughout treatment.

Common · Usually Manageable

Nausea and vomiting
Fatigue
Anaemia (low red blood cell count)
Decreased appetite
Diarrhoea
Headache
Altered taste

Serious · Report Immediately

Myelodysplastic syndrome (MDS) / acute myeloid leukaemia (AML)
Pneumonitis (lung inflammation)
Severe or persistent low blood counts
Venous thromboembolism (blood clots)

⚠ Call your doctor immediately if you experience:

New or worsening breathlessness, dry cough, or fever (possible pneumonitis)
Unusual bruising, prolonged bleeding, or signs of infection (possible blood disorder)
Sudden leg swelling/pain, chest pain, or breathlessness (possible blood clot)

How to Take Olanib 150 mg

Standard dose: 300 mg (two 150 mg tablets) twice daily, for a total of 600 mg per day, with or without food.

1
Two tablets, twice daily — approximately 12 hours apart, e.g. morning and evening.
2
Swallow tablets whole with a glass of water. Do not chew, crush, or dissolve them.
3
Avoid grapefruit and Seville oranges (including marmalade) — these significantly increase olaparib blood levels via CYP3A4 interaction, potentially to dangerous levels.
4
If you miss a dose, take your next dose at the scheduled time. Do not take an extra dose to make up for a missed one.
5
Storage: below 30°C, in the original container, protected from moisture and light.

Caregiver Guidance

♥
Track blood test appointments closely — regular Complete Blood Count (CBC) monitoring is essential, especially in the first year, to catch low blood counts early.
♥
Watch for fever or unusual bruising — report any signs of infection, unexplained bruising, or prolonged bleeding to the oncologist promptly.
♥
Help manage twice-daily dosing — set alarms 12 hours apart and remove grapefruit products from the household to avoid accidental interaction.

If the Medicine Stops Working

Resistance to olaparib can develop through restoration of homologous recombination repair function — for example, through secondary BRCA mutations that reverse the original mutation, or upregulation of drug efflux pumps that reduce intracellular drug levels. If disease progression is detected, your oncologist will typically reassess treatment options based on the specific clinical setting — this may include a switch to chemotherapy, a different PARP inhibitor, or enrolment in a clinical trial, depending on prior treatment history and current disease status.

Frequently Asked Questions

Do I need genetic testing before starting Olanib?

Yes. Olaparib is only approved for patients with confirmed BRCA1/2 mutations or, in some indications, broader homologous recombination repair (HRR) gene alterations. Your oncologist will arrange germline or tumour genetic testing before prescribing to confirm you are an appropriate candidate.

What is the recommended dosage for Olanib 150 mg?

The standard dosage is 300 mg taken twice daily — that means two 150 mg tablets in the morning and two 150 mg tablets in the evening, for a total of four tablets (600 mg) per day. Your oncologist may adjust this dose based on blood test results or side effects.

Can I take Olanib with food?

Yes, Olanib tablets can be taken with or without food. However, if you experience nausea (a common side effect), taking the medication with a light, bland meal may help settle your stomach.

Why must I avoid grapefruit while taking Olanib?

Grapefruit and Seville oranges contain compounds that inhibit the CYP3A4 enzyme responsible for metabolising olaparib. This can cause olaparib levels in your blood to rise to potentially harmful levels, increasing the risk of side effects. This restriction applies for the entire duration of treatment.

How long will I need to take Olanib?

Duration varies by indication. As maintenance therapy after chemotherapy response, many patients continue for up to 2 years or until disease progression. In other settings, treatment continues until disease progression or unacceptable toxicity. Your oncologist will determine the appropriate duration for your specific situation.

How do I order Olanib through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription and confirmation of BRCA/HRR testing. Our team will verify the prescription, confirm availability and pricing for your country, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.

This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.

Clinical References

Moore K, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO-1). NEJM 2018;379:2495–2505.
Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation (OlympiAD). NEJM 2017;377:523–533.
NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. V3.2026.
de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer (PROfound). NEJM 2020;382:2091–2102.